Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

US Patent 11872282 · Granted Jan 16, 2024

Estimated economic value: $205,700,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of ovarian cancer in patients with ascites using a specific binding ag2020
Treatment of ovarian cancer in patients with ascites using a specific binding ag2020
Detecting immunological changes in HIV infected patient samples1992